Avidity Partners Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-203,600
Closed -$5.07M 65
2025
Q4
$5.07M Sell
203,600
-162,800
-44% -$4.11M 1.46% 15
2025
Q3
$9.34M Buy
+366,400
New +$9.04M 2.12% 12
2023
Q3
Sell
-1,117,467
Closed -$41M 97
2023
Q2
$41M Buy
+1,117,467
New +$43.5M 1.43% 29
2022
Q1
Sell
-2,090,000
Closed -$123M 103
2021
Q4
$123M Buy
2,090,000
+1,063,200
+104% +$52.7M 2.62% 9
2021
Q3
$44.2M Buy
+1,026,800
New +$45.5M 0.98% 34

Other funds holding PFE

Avidity Partners Management's PFE Position: Q1 2026 in Review

Avidity Partners Management sold out of Pfizer (PFE) in Q1 2026, closing a stake of 203,600 shares — an estimated $5.07M sold.

Avidity Partners Management first reported a position in PFE in Q3 2021 and held it in 5 quarters. The position peaked at $123M in Q4 2021. 2,952 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Avidity Partners Management reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Avidity Partners Management sold 203,600 Pfizer shares in Q1 2026, an estimated $5.07M.
  • Avidity Partners Management first reported a position in Pfizer in Q3 2021 and held it in 5 quarters.
  • Avidity Partners Management's Pfizer position peaked at $123M in Q4 2021.
  • 2,952 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.